Screener
Supernus Pharmaceuticals SUPN Business Segments — Total external development program expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept supn:ExternalResearchAndDevelopmentExpense.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Qelbree | 2,364 | 4,413 |
| ZURZUVAE | 82 | — |
| Early-stage programs and other expenses | 6,565 | 3,213 |
| Total external development program expenses | 27,678 | 16,432 |
| Internal employee-related expenses | 11,760 | 10,495 |
| Total research and development expenses | 39,438 | 26,927 |
| Other segment items(a) | 21,996 | 29,017 |
| Net loss | $(2,293) | $(11,827) |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Supernus Pharmaceuticals's business segments — total external development program expenses?
- Supernus Pharmaceuticals (SUPN) reported business segments — total external development program expenses of $27.68M in Q1 2026.
- How has Supernus Pharmaceuticals's business segments — total external development program expenses changed year-over-year?
- Supernus Pharmaceuticals's business segments — total external development program expenses increased by 68.4% year-over-year, from $16.43M to $27.68M.
- What is the long-term trend for Supernus Pharmaceuticals's business segments — total external development program expenses?
- Over 3 years (2022 to 2025), Supernus Pharmaceuticals's business segments — total external development program expenses has grown at a 13.1% compound annual growth rate (CAGR), from $42.99M to $62.17M.
- What does business segments — total external development program expenses mean?
- Represents payments made to third-party organizations, such as contract research organizations, for clinical trials and drug development activities. This metric highlights the company's reliance on external partners to advance its pipeline of neurological treatments.
Ask your AI about Supernus Pharmaceuticals's business segments — total external development program expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude